Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Screening for bronchial carcinoma].

D Moro-Sibilot1, B Milleron,

  • 1Groupe de recherche sur le cancer bronchique INSERM EMI 9924, Conseil scientifique Dépiscan, CHU A. Michallon, Grenoble, France. DMoro.pneumo@chu-grenoble.fr

Revue Des Maladies Respiratoires
|January 14, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Innovative therapeutic cancer vaccine PDC<sup>∗</sup>lung01 with or without anti-PD-1: an open-label, dose-escalation phase I/II study in non-small-cell lung cancer.

ESMO open·2025
Same author

Lorlatinib for advanced ROS1+ non-small-cell lung cancer: results of the IFCT-1803 LORLATU study.

ESMO open·2022
Same author

IFCT-1502 CLINIVO: real-world evidence of long-term survival with nivolumab in a nationwide cohort of patients with advanced non-small-cell lung cancer.

ESMO open·2021
Same author

[Implication of bronchopulmonary cancer patients in thoracic oncology].

Revue des maladies respiratoires·2021
Same author

Revue des maladies respiratoires actualites·2021
Same author

Consolidation nivolumab and ipilimumab versus observation in limited-disease small-cell lung cancer after chemo-radiotherapy - results from the randomised phase II ETOP/IFCT 4-12 STIMULI trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2021
Same journal

[French version of the guidelines for connective tissue disease-associated ILD].

Revue des maladies respiratoires·2026
Same journal

[Pulmonary expression of an asymptomatic lysosomal storage disorder].

Revue des maladies respiratoires·2026
Same journal

[Factors associated with FEV1 evolution in cystic fibrosis patients treated by CFTR modulator tritherapy].

Revue des maladies respiratoires·2026
Same journal

[Subacute pulmonary coccidioidomycosis: A differential diagnosis of lung cancer].

Revue des maladies respiratoires·2026
Same journal

[Relevance of the ACT score in severe asthma with obesity: A pilot study].

Revue des maladies respiratoires·2026
Same journal

[Automated analysis of mandibular movements for the screening of obstructive sleep apnea].

Revue des maladies respiratoires·2026
See all related articles

Screening for bronchial carcinoma using low-dose CT scans shows promise for early detection. However, randomized controlled trials are needed to prove if this lung cancer screening reduces mortality.

Area of Science:

  • Oncology
  • Radiology
  • Public Health

Background:

  • Bronchial carcinoma is a leading cause of cancer mortality.
  • Unlike breast and colon cancers, the mortality benefit of lung cancer screening is not yet established.
  • Advancements in low-dose spiral CT scanning have renewed interest in lung cancer screening.

Purpose of the Study:

  • To evaluate the potential of low-dose spiral CT scanning for early detection of bronchial carcinoma.
  • To assess preliminary data suggesting improved survival rates for lung cancers detected via screening.
  • To determine if current evidence supports widespread lung cancer screening programs.

Main Methods:

  • Review of preliminary studies on low-dose spiral CT scanning for lung cancer detection.
  • Analysis of data on tumor stage at diagnosis for CT-detected lung cancers.

Related Experiment Videos

  • Consideration of survival data from screened populations.

    • Main Results:

    • Preliminary studies indicate that CT scanning detects 2/3 of bronchial carcinomas at an early stage.
    • Some data suggest a potential improvement in survival for tumors discovered through screening.
    • Definitive proof of mortality reduction through lung cancer screening is still lacking.

    Conclusions:

    • Mass screening for bronchial carcinoma using CT scanning is not currently recommended.
    • High-risk individuals should be encouraged to participate in randomized controlled trials.
    • Further research is essential to confirm or refute the effectiveness of CT screening in reducing lung cancer mortality.